Enzymatica Publ Valuation
| ENZY Stock | SEK 2.82 0.08 2.76% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. Enzymatica publ AB shows a prevailing Real Value of kr2.11 per share. The current price of the firm is kr2.82. Our model computes the value of Enzymatica publ AB from reviewing the firm fundamentals such as Current Valuation of 613.36 M, profit margin of (1.12) %, and Shares Outstanding of 164.26 M as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Enzymatica Publ's price fluctuation is dangerous at this time. Calculation of the real value of Enzymatica publ AB is based on 3 months time horizon. Increasing Enzymatica Publ's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Enzymatica Publ's intrinsic value may or may not be the same as its current market price of 2.82, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.82 | Real 2.11 | Hype 2.9 | Naive 2.83 |
The intrinsic value of Enzymatica Publ's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Enzymatica Publ's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Enzymatica publ AB helps investors to forecast how Enzymatica stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Enzymatica Publ more accurately as focusing exclusively on Enzymatica Publ's fundamentals will not take into account other important factors: Enzymatica Publ Total Value Analysis
Enzymatica publ AB is currently anticipated to have takeover price of 613.36 M with market capitalization of 681.8 M, debt of 1.12 M, and cash on hands of 64.82 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Enzymatica Publ fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
613.36 M | 681.8 M | 1.12 M | 64.82 M |
Enzymatica Publ Investor Information
About 64.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.37. Enzymatica publ AB had not issued any dividends in recent years. The entity had 2761:2760 split on the 5th of August 2022. Enzymatica publ AB is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.Enzymatica Publ Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Enzymatica Publ has an asset utilization ratio of 36.45 percent. This implies that the Company is making kr0.36 for each dollar of assets. An increasing asset utilization means that Enzymatica publ AB is more efficient with each dollar of assets it utilizes for everyday operations.Enzymatica Publ Ownership Allocation
Enzymatica Publ holds a total of 164.26 Million outstanding shares. Enzymatica publ AB shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 64.15 percent of Enzymatica publ AB outstanding shares that are owned by insiders denotes they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Enzymatica Publ Profitability Analysis
The company reported the revenue of 57.24 M. Net Loss for the year was (45.39 M) with profit before overhead, payroll, taxes, and interest of 33.35 M.About Enzymatica Publ Valuation
The stock valuation mechanism determines Enzymatica Publ's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Enzymatica publ AB based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Enzymatica Publ. We calculate exposure to Enzymatica Publ's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Enzymatica Publ's related companies.Enzymatica AB, a life science company, develops and sells medical devices for infection-related diseases in Sweden and internationally. Enzymatica AB was incorporated in 2007 and is based in Lund, Sweden. Enzymatica operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange. It employs 24 people.
8 Steps to conduct Enzymatica Publ's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Enzymatica Publ's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Enzymatica Publ's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Enzymatica Publ's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Enzymatica Publ's revenue streams: Identify Enzymatica Publ's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Enzymatica Publ's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Enzymatica Publ's growth potential: Evaluate Enzymatica Publ's management, business model, and growth potential.
- Determine Enzymatica Publ's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Enzymatica Publ's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Enzymatica Stock Analysis
When running Enzymatica Publ's price analysis, check to measure Enzymatica Publ's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enzymatica Publ is operating at the current time. Most of Enzymatica Publ's value examination focuses on studying past and present price action to predict the probability of Enzymatica Publ's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enzymatica Publ's price. Additionally, you may evaluate how the addition of Enzymatica Publ to your portfolios can decrease your overall portfolio volatility.